{"a":[{"_":"Regenxbio gene therapy refiling plan derailed by FDA hold over spine MRI findings","$":{"href":"/biotech/fda-clinical-hold-derails-regenxbio-gene-therapy-refiling-plan","hreflang":"en"}}]}
RegulatoryrejectedRGX-121Negative
AI Analysis
Summary
The FDA has placed a clinical hold on Regenxbio's RGX-121 gene therapy due to asymptomatic spine MRI findings, blocking the company's plans to refile for approval after a previous rejection.
Outcome Details
FDA clinical hold placed over asymptomatic spine MRI findings
Importance:9/10
Sentiment:
-0.95
clinical holdgene therapyFDA regulatoryprogram derailment
Related Companies
Read the original article
Published by FierceBiotech on August 24, 2026 7:51 AM